EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint Pharmaceuticals told investors its Phase 3 wet AMD program was "on track" days before disclosing that DURAVYU missed the prespecified primary endpoint. SueWallSt notifies investors of a pending investigation into on behalf of EYPT investors who suffered losses. NEW YORK, Aug. 20,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.